Drugs / hAd5-S-Fusion+N-ETSD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04710303 | Mar 2021 → Aug 2022 | COVID-19 | ImmunityBio, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hAd5-S-Fusion+N-ETSD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04710303 ↗ |
| Modality | Vaccine | “vector-based targeting vaccine” NCT04710303 ↗ |
| Route | Intranasal | “2 × 10e10 VP per nostril” NCT04710303 ↗ |